SCHEMBL287170

SCHEMBL287170

CCCCCCc1cc2ccc(Cl)cc2[nH]1

nearest known ligand 0.51

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 5/20 0.51
CTSV O60911 1/20 0.48
CTSL P07711 1/20 0.48
GHSR Q92847 3/20 0.45
GPR84 Q9NQS5 10/20 0.44
LOXL2 Q9Y4K0 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3701458 0.88 LOXL2 (0.57) CTSVCTSLGHSRGPR84LOXL2
SCHEMBL3698687 0.88 LOXL2 (0.57) CTSVCTSLGHSRGPR84LOXL2
SCHEMBL11092362 0.81 CTSV (0.48) CTSVCTSLGHSRGPR84
SCHEMBL13624442 0.80 ALOX15 (0.50) ALOX15LOXL2
SCHEMBL1122056 0.80 GPR17 (0.48) ALOX15
SCHEMBL10513013 0.79 CTSV (0.63) CTSVCTSLGHSRGPR84LOXL2
SCHEMBL3702698 0.79 CTSV (0.63) CTSVCTSLGHSRGPR84LOXL2
SCHEMBL10513049 0.79 CTSV (0.63) CTSVCTSLGHSRGPR84LOXL2
SCHEMBL11415263 0.79 CTSV (0.63) CTSVCTSLGHSRGPR84LOXL2
SCHEMBL31041747 0.79 CTSV (0.63) CTSVCTSLGHSRGPR84LOXL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9464048-B2 5-oxo-ETE receptor antagonist compounds FLORIDA INSTITUTE OF TECHNOLOGY (US) 2016-10-11 US disclosed
US-20140323535-A1 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) 2014-10-30 US disclosed
EP-2427430-B1 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS UNIV MCGILL (CA) 2014-09-10 EP disclosed
US-8809382-B2 5-oxo-ETE receptor antagonist compounds THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) 2014-08-19 US disclosed
US-20120122942-A1 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS FLORIDA INSTITUTE OF TECHNOLOGY 2012-05-17 US disclosed
EP-2427430-A1 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS The Royal Institution for the Advancement of Learning / McGill University (CA) 2012-03-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122942-A1 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS OXER1, PTGIR, EDNRA ALOX15 41/4885CTSV 1540/4885CTSL 1135/4885
US-20140323535-A1 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS OXER1, PTGIR, EDNRA ALOX15 41/4885CTSV 1540/4885CTSL 1135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.